Time to test the ‘lipoprotein(a) hypothesis’?

Elevated lipoprotein(a) is now recognised as having a causal role in cardiovascular disease and aortic valve stenosis. Management of elevated lipoprotein(a), however, has been difficult with the lack of specific treatments. Latebreaker results with a novel antisense oligonucleotide containing an acetyl-galactosamine (GalNac3), now provide a strong rationale for a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.

Read the report »

Dr Robert S. Rosenson (Icahn School of Medicine at Mount Sinai, New York, USA) discusses these data

Watch the video »

Other News

REDUCE-IT: Professor Stephen Nicholls (University of Adelaide, Australia) discusses this landmark study
	Nicholls: REDUCE-IT take home messages		Nicholls: REDUCE-IT- does the formulation matter?

OSLER-1 with evolocumab: Final 5-year data

Read the report »

Like us on Facebook For the latest updates, PCSK9 news and analysis. Follow us on Twitter Hot topics, news and conference reports. YouTube Channel For videos, interviews and webcasts from leading experts.